Core Insights - Vivoryon Therapeutics N.V. presented Phase 2 clinical study data for varoglutamstat at the ASN Kidney Week 2025, highlighting its potential to stabilize and improve kidney function in patients [2][3][7] Group 1: Clinical Study Findings - The poster presented data from the VIVIAD Phase 2B randomized clinical trial, showing a significant correlation between the reduction of the anti-inflammatory biomarker pE-CCL2 and improved kidney function as measured by eGFR [4][6] - A decrease in pE-CCL2 levels at week 48 was statistically correlated with a positive eGFR slope over time, indicating the potential effectiveness of varoglutamstat in treating kidney disease [4][5] Group 2: Company Strategy and Future Plans - Vivoryon plans to confirm the compelling data from its Phase 2 studies by conducting a dedicated Phase 2B clinical study in patients with advanced diabetic kidney disease, contingent on additional funding and partnerships [5][8] - The company emphasizes the importance of its innovative approach to treating diabetic kidney disease and other chronic kidney disorders through the inhibition of glutaminyl-cyclases with varoglutamstat [5][8]